20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults

Autor: Matt, Shirley
Rok vydání: 2022
Předmět:
Zdroj: Drugs. 82:989-999
ISSN: 1179-1950
0012-6667
DOI: 10.1007/s40265-022-01733-z
Popis: The introduction of multi-valent pneumococcal vaccines around the world, such as the 13-valent pneumococcal conjugate vaccine (PCV13), has had a significant effect in reducing the burden of disease caused by Streptococcus pneumoniae infection globally. However, S. pneumoniae serotypes not covered by PCV13 still cause significant disease. A 20-valent pneumococcal conjugate vaccine (PCV20; Prevnar20Pneumonia and other diseases caused by infection with the bacterium Streptococcus pneumoniae are a significant health concern. The introduction of vaccines targeting multiple S. pneumoniae serotypes [such as the 13-valent pneumococcal conjugate vaccine (PCV13)] has had a significant effect in reducing pneumococcal disease; however, serotypes not covered by PCV13 still cause significant disease. Recently, a new vaccine [20-valent pneumococcal conjugate vaccine (PCV20; Prevnar20
Databáze: OpenAIRE
Externí odkaz: